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Direct visualization of a Fe(IV)–OH intermediate in
a heme enzyme
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Andreas Ostermann5, Juliette M. Devos2, Pierre Aller6, Matthew P. Blakeley2, Peter C.E. Moody1
& Emma L. Raven7
Catalytic heme enzymes carry out a wide range of oxidations in biology. They have in
common a mechanism that requires formation of highly oxidized ferryl intermediates. It is
these ferryl intermediates that provide the catalytic engine to drive the biological activity.
Unravelling the nature of the ferryl species is of fundamental and widespread importance. The
essential question is whether the ferryl is best described as a Fe(IV)¼O or a Fe(IV)–OH
species, but previous spectroscopic and X-ray crystallographic studies have not been able to
unambiguously differentiate between the two species. Here we use a different approach. We
report a neutron crystal structure of the ferryl intermediate in Compound II of a heme
peroxidase; the structure allows the protonation states of the ferryl heme to be directly
observed. This, together with pre-steady state kinetic analyses, electron paramagnetic
resonance spectroscopy and single crystal X-ray ﬂuorescence, identiﬁes a Fe(IV)–OH species
as the reactive intermediate. The structure establishes a precedent for the formation of
Fe(IV)–OH in a peroxidase.
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T
he family of heme-containing peroxidase enzymes is
widespread in biology. They catalyse the H2O2-dependent
oxidation of a range of different substrates, and in doing so
underpin a number of essential biological processes in bacterial,
yeast, plant, fungal and mammalian systems1,2. The key to their
catalytic power is the formation of two transient, oxidized heme
intermediates. These intermediates—which are both FeIV (ferryl)
species but differ in the oxidation state of the porphyrin
ring—form sequentially during catalysis. Both intermediates
were originally observed in horseradish peroxidase but were
mistakenly interpreted as enzyme–substrate complexes: the ﬁrst
(green) intermediate was discovered by Theorell, and the second
(red) intermediate by Keilin and Mann3,4. They were eventually
given the names Compound I and Compound II to differentiate
them from the enzyme–substrate complex5,6. These same two
intermediates are used widely in numerous other O2-dependent
catalytic heme enzymes, most notably the cytochrome P450s, the
nitric oxide synthases, the terminal oxidases plus the heme
dioxygenases.
Many years have passed since the ﬁrst observations, but
establishing the nature of these transient ferryl species remains a
fundamental question7–10. A particular focus has been the nature
of the ferryl group in Compounds I and II, and whether it is best
described as an Fe(IV)¼O or a Fe(IV)–OH species. This is
important because the bonding interactions and the protonation
state of the ligand bound to the iron controls the reactivity—and
hence the biological usefulness—of each intermediate. But this
conceptually simple question has proved ﬁendishly difﬁcult to
answer, and thus has become highly controversial. Part of the
problem is that spectroscopic approaches—which have mainly
used EXAFS, resonance Raman, and Mossbauer—are only
indirect reporters of the protonation state of the ligand; none
can directly visualize individual protons and so the picture
emerging from spectroscopic analyses has been ambiguous, with
some data supporting a Fe(IV)¼O formulation and other data
supporting Fe(IV)–OH. X-ray crystallographic work later
followed. Long Fe–O bond lengths were reported and, as an
indirect measure of protonation state, were interpreted as
consistent with Fe(IV)–OH. But photoreduction is now known
to affect X-ray structures, and in the case of ferryl intermediates
leads to reduction of the heme. Early structures were thus
undermined. Photoreduction problems likely affect some of the
spectroscopic experiments as well11,12.
We have approached the question in a completely different
way. Using neutron diffraction, hydrogen and deuterium atoms
are directly visible, and photoreduction does not occur at all13.
Thus, if the considerable difﬁculties of a neutron crystallographic
experiment on a reactive enzyme intermediate trapped at low
temperature can be overcome, then the approach is potentially
transformative. In this work, we have used the approach to
examine the Compound II intermediate of a heme peroxidase.
Results
Comparison of relevant peroxidases. Ascorbate peroxidase
(APX) catalyses the H2O2-dependent oxidation of ascorbate using
the Compound I and Compound II intermediates. APX has
high-sequence identity to cytochrome c peroxidase (CcP), which
has served as a benchmark for heme enzyme catalysis over many
years. But the experimental difﬁculty of isolating Compound II is
simpliﬁed considerably by working with APX because Compound
I in APX exists as a ferryl heme and a porphyrin p-cation
radical14,15, and is distinct from its Compound II, which contains
only a ferryl species. This is not the case in CcP, as Compound I
of CcP contains a ferryl heme and a tryptophan radical16, which is
not easily differentiated from its Compound II (ferryl heme only)
in ultraviolet-visible spectra.
Stopped ﬂow and EPR spectroscopy. Reaction of ferric APX with
m-chloroperbenzoic acid (m-CPBA) initially yields a Compound I
intermediate (lmax¼ 409, 527, 575sh, 649 nm; Fig. 1a); this decays
rapidly to a Compound II intermediate (lmax¼ 415, 528, 558 nm;
see Fig. 1a and Supplementary Fig. 1), which is stable over long
(500 s) timescales. The spectra of both Compound I and
Compound II are pH-independent (Supplementary Fig. 2a,b).
Electron paramagnetic resonance (EPR) spectra conﬁrm these
observations (Fig. 1b). Initial formation of Compound I as the
ﬁrst intermediate on reaction of ferric APX with m-CPBA over
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Figure 1 | Formation of Compound II. (a) Spectra obtained on reaction of ferric APX (black spectrum, at t¼0) with m-CPBA (10 equivalents), monitored
over 100 s, showing formation ﬁrst of Compound I (red spectrum) and then Compound II (blue spectrum). Absorbance values in the visible region have
been multiplied by a factor of four. Conditions: 10mM sodium phosphate, 150mM KCl pH 7.0, 10.0 C. Inset: Single crystal ultraviolet-visible spectra
(100K) of Compound II formed by reaction of ferric APX with m-CPBA showing the characteristic peaks (B530 and B560nm) in the visible region.
(b) 9GHz EPR spectra of a solution of ferric APX (top spectrum, black), with the expected high-spin (g>¼6 and g8¼ 2) and low-spin (g1¼ 2.69, g2¼ 2.22,
g3¼ 1.79) heme resonances indicated; The spectrum of Compound II (middle spectrum, blue) prepared by reaction of ferric APX with 20 equivalents of
m-CPBA and ﬂash-frozen after 40 s; The bottom spectrum is same sample as the middle spectrum but recorded after 20 days. The spectra in
Supplementary Figs 1 and 3b show that the pattern of reactivity with H2O2 is the same as with m-CPBA, giving the same Compound II species, in solution
and in single crystals. Spectra were recorded at 7.5 K, 0.4 mT modulation amplitude, 1 mW power, 4 scans, 2,048 points.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13445
2 NATURE COMMUNICATIONS | 7:13445 |DOI: 10.1038/ncomms13445 | www.nature.com/naturecommunications
short (7 s) timescales is apparent (new axial resonance at g¼ 3.54;
Supplementary Fig. 3a). Over longer timescales (40 s), the ferric
signals disappear and no new resonances are observed in
Compound II (except for a very minor component from a
radical signal (o5%)) (Fig. 1b). Our spectra are in agreement
with early EPR analyses on APX-I and APX-II (ref. 14). There is
no evidence for a low-spin, paramagnetic Fe(III)–OH species in
the EPR spectrum of Compound II (see also Supplementary
Fig. 1g,h). These spectra demonstrate that the Compound II
species is EPR-silent, conﬁrming the presence of a ferryl heme.
The spectrum of Compound II is stable when stored at 77 K over
20 days (Fig. 1b).
Single crystal analyses. Having characterized the reactivity
in solution (as above), we then produced Compound II in
crystallo and examined the crystals using single crystal
microspectrophotometry and X-ray ﬂuorescence. Single crystal
microspectrophotometry at 100K on crystals of ferric APX
reacted with m-CPBA showed absorption peaks for Compound II
in the visible region (lmax¼ 530, 560 nm; Fig. 1a, inset) that
agree with those in solution (Fig. 1a). The data indicate a
high-percentage conversion in the crystal, and show that the
predominant species is Compound II; we cannot rule out the
presence of minor amounts of unreacted ferric enzyme (which are
likely to be ferric hydroxide at this temperature). To conﬁrm
the oxidation state of the iron in the crystal, Fe K-edge X-ray
ﬂuorescence spectra were collected on a single crystal of
Compound II. This showed a shift of the edge to higher energy
compared with crystals of the ferric enzyme (Supplementary
Fig. 3c), consistent with an increase in the iron oxidation state
(from III to IV). Together, these spectra conﬁrm the formation of
Compound II and the presence of Fe(IV) in the crystal.
Neutron diffraction. The neutron structure of Compound II,
prepared as above by reaction with m-CPBA, was solved at 100K
using data to 2.2 Å resolution. Data and joint X-ray/neutron
reﬁnement statistics are shown in Supplementary Table 1.
Neutron and X-ray maps in the region of the heme are shown in
Fig. 2a,b, respectively. Detailed views of the overall protein
structure, individual active site residues and hydrogen bonding
structure in the active site are shown in Supplementary Fig. 4. On
the distal side of the heme, Trp41 is deuterated on Ne, and Arg38
is fully deuterated and is orientated away from the ferryl heme
(previously referred to as the ‘out’ position17). The distal histidine
residue, His42, is doubly protonated (on Ne and Nd).
An Fo–Fc neutron map calculated by omitting the ligand on the
distal side of the heme iron shows a positive difference density
peak that was interpreted as arising from OD (Fig. 2c). The
identity of this ligand was supported by calculations using an
oxygen atom alone (that is, as in Compound I (ref.18)), which
resulted in a positive difference peak at the D position
(Supplementary Fig. 5a). There is no evidence from the maps
for water occupancy at the distal site; if the distal site was
modelled as D2O, the other D site showed negative difference
density (Supplementary Fig. 5b). No residual difference density
was observed after reﬁnement as OD.
Multi-crystal X-ray crystallography. The measured Fe–O bond
length is 1.88Å (Fig. 2c). This is longer than would be expected for
an unprotonated Fe(IV)¼O double bond species19 and this
distance is in the range expected for a single bonded Fe(IV)–OH
species. It has been previously established using multi-crystal X-ray
methods (to minimize photoreduction), that the corresponding
bond length in CcP-I is 1.63Å17. In this paper, independent
veriﬁcation of the Fe–O bond length in Compound II using the
same multi-crystal X-ray methods (see ‘Methods’ section) yielded a
bond length of 1.87Å (Supplementary Fig. 5c), which agrees with
the neutron data above (Fig. 2c) and with previous X-ray data for
APX-II (ref. 17). Putting aside for one moment the caveats that
bond lengths in X-ray experiments are not determined precisely at
this resolution, nor indeed that they report directly on protonation
state, the salient point is that the Fe–O bond length measured here
for Compound II is longer than that of Compound I of CcP
determined by reliable X-ray determinations (that is, where
photoreduction has been minimized)17,20. There is also close
agreement with recent Fe–O bond length determinations in
Compound II of P450 (1.84Å (ref. 21)).
Discussion
Taken together, the data from the crystallographic and spectro-
scopic experiments are all consistent with the presence of an
Fe(IV)–OH species in Compound II of APX. A broader
comparison with the Compound I and Compound II inter-
mediates of the related P450 enzymes is relevant (Fig. 3). The two
classes of heme enzymes differ in their heme axial ligation—the
P450s contain a Cys thiolate ligand on the proximal side of the
1.88 Å
a b c
Figure 2 | Neutron crystal structure of Compound II. (a) Nuclear scattering density is shown in cyan (contoured at 1.5 s). (b) Electron density is
shown in magenta (contoured at 1.5 s). (c) The neutron Fo–Fc difference density calculated by omitting the distal ligand is shown in black (contoured at 3.0
s), this is also shown as a stereo image in Supplementary Fig. 6. The O atom of the OD is positioned at 1.88Å from the heme iron. Colour scheme:
hydrogen—green; deuterium—white; carbon—yellow; oxygen—red; nitrogen—blue; and iron—brown sphere.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13445 ARTICLE
NATURE COMMUNICATIONS | 7:13445 | DOI: 10.1038/ncomms13445 | www.nature.com/naturecommunications 3
heme, while the peroxidases have a histidine ligand instead.
Compound I of cytochrome P450 has a radical on the porphyrin
or the thiolate ligand (or delocalized between the two), and the
ferryl heme is unprotonated22. Compound I in two closely related
thiolate-ligated enzymes—aromatic peroxygenase (APO) and
chloroperoxidase—are also assigned as Fe(IV)¼O/porphyrin
p-cation radical intermediates7,23. There is no information yet on
a histidine-ligated peroxidase with a Compound I carrying a
porphyrin p-cation radical. The best information comes from the
atypical CcP (containing a Trp radical instead16), which also
contains Fe(IV)¼O (ref. 18).
Compound II in the bacterial CYP-158 P450 enzyme is a
protonated Fe(IV)–OH species21. This pattern of unprotonated/
protonated ferryl in Compound I/II in P450 is mirrored in both
APO and chloroperoxidase24,25 (Fig. 3). This means that there is
a large ‘uplift’ in the ferryl pKa from Compound I (Fe(IV)¼O) to
Compound II (Fe(IV)–OH), which leads to the protonation
event. What causes this shift in pKa of the ferryl heme in these
thiolate-ligated systems is not clear, although bond length
changes to the axial ligand26, other hydrogen bond changes in
the heme active site, and even distortions of the heme may all
play a role as part of a complex mixture of variables that, together,
dictate the nature and reactivity of the ferryl heme.
It has been widely assumed that formation of a Fe(IV)–OH
species is not possible in the peroxidases, but our data
demonstrate that it is. This offers a different perspective on the
utilization of these ferryl intermediates across the family of heme
enzymes. It remains to be seen whether other members of the
peroxidase family behave similarly, but there is recent evidence
that the ferryl heme could be protonated under certain conditions
in other histidine-ligated heme enzymes27,28. The mechanisms of
proton delivery are poorly understood. They are likely to involve
networks of hydrogen-bonded residues and water molecules that
connect the distal iron ligands all the way to the solvent
surface28–32. As further new information emerges, the data
presented here will help to lay a foundation for understanding the
subtle and varied mechanisms that control proton delivery and
biological reactivity in cytochrome P450 and other catalytic heme
enzymes.
Methods
Protein expression and puriﬁcation. Soybean cytosolic APX, in a pLEICS-03
vector carrying kanamycin resistance and a TEV cleavable N-terminal His tag, was
expressed in E. coli BL21 (DE3) cells. Cells were grown in 2-YT media for 16 h at
37 C and protein expressed without induction with IPTG. Cells were collected by
centrifugation (4,000g at 277 K for 20min) and protein puriﬁed as previously
described33–35.
Stopped-ﬂow kinetics. Pre-steady state stopped-ﬂow experiments were carried
out using an Applied Photophysics SX.18MV stopped-ﬂow spectrometer. All
experiments were carried out at 10 C unless otherwise stated, using 10mM sodium
phosphate buffer, 150mM KCl pH 7.0 (for APX) or pH 6.5 (for CcP). Spectral
deconvolution was performed by global analysis and numerical integration
methods using Pro-Kineticist software (Applied Photophysics Ltd). In all kinetic
experiments, Compound II was formed in 93–95% yield.
Formation of Compounds I and II was followed in single mixing mode by
mixing ferric enzyme (typically 2–3mM) with 2–20 equivalents of H2O2 or
m-chloroperbenzoic acid (m-CPBA) and time-dependent spectral changes
monitored using a photodiode array detector. Data were ﬁtted to a one-step model
A-B, where A¼ ferric enzyme and B¼Compound I (for Compound I
formation) and A¼Compound I and B¼Compound II (for Compound II
formation).
Compound II was also generated directly, under anaerobic conditions, by
reaction of peroxide with the ferrous form of the enzyme. For these experiments,
the sample handling unit of the stopped-ﬂow instrument was housed in an
anaerobic glove box (Belle Technology Ltd., [O2]o5 p.p.m.) and was used in the
single mix mode. Ferrous enzyme, produced by titration of ferric APX (5–10 mM)
with 2–5 equivalents of sodium dithionite, was mixed with 10 equivalents of
H2O2. Time-dependent spectral changes accompanying Compound II formation
were followed and data analysis carried out as outlined above.
To avoid enzyme instability problems (below pH 4.5 and above pH 11.5), the pH-
jump method was used to investigate the pH-dependence of the spectra of
Compounds I and II. Enzyme samples were prepared in water, adjusted to pH 7 with
trace amounts of phosphate buffer (5mM, pH 8.0). For Compound I formation, the
enzyme was mixed with a stoichiometric amount of H2O2, which was made up in a
buffer of twice the desired ﬁnal concentration. The buffers used were citrate–
phosphate in the pH range 4.0–6.0 (0.2M), sodium carbonate–bicarbonate buffer in
the range 8.0–10.5 (0.2M) and sodium hydrogen phosphate (0.2M) at pH 11.5. For
Compound II formation, the sequential mix method was used and the enzyme was
ﬁrst mixed with H2O2 (also prepared in water at pH 7.0 as outlined above), the
reaction allowed to age for 80 s to enable complete conversion to Compound II
before a second mix with 0.2M buffer. In all experiments, the pH of the solution was
measured after mixing to ensure consistency.
EPR spectroscopy. Continuous-wave EPR spectra were recorded at 9.4GHz on a
Bruker EMX spectrometer with a Super-high-Q rectangular cavity and an Oxford
ESR-900 liquid helium cryostat. The operating conditions are stated in the Figure
legends. Samples of APX in solution were prepared in 10mM potassium phosphate
buffer, 150mM KCl, pH 7.0. Compounds I and II were prepared by manually
mixing ferric APX (370mM) with an equivalent volume of m-CPBA or H2O2
solution directly in 4mm quartz EPR tubes, followed by ﬂash freezing in liquid
nitrogen. We found that APX crystals are not large enough for single crystal EPR
experiments because the absolute intensity of the EPR resonance for APX is too low.
Crystallization. Crystallization of APX was a modiﬁcation of previous procedures
and gave larger crystals (some as large as 1 0.6 0.4mm3) than previously
(typically 0.15 0.075 0.075mm3 (refs 31,36). Crystals were grown by vapour
diffusion hanging drops made up of 2–4ml protein (20mgml 1 in 10mM
potassium phosphate pH 7.0, 150mMKCl) and an equal volume of precipitant
(2.25M Li2SO4, 0.1M HEPES pH 8.3–8.9). The drop was allowed to equilibrate
with 700ml of precipitant. The crystals appeared in 2–14 days. Deuteration of APX
was carried out by crystallizing the protein with the mother liquor made up with
D2O. Once the crystals were fully grown, the crystals were transferred and kept in
the mother liquor with D2O until needed. Formation of Compound II in APX
crystals for X-ray and neutron data collection was achieved by soaking the crystals
in m-chloroperbenzoic acid (m-CPBA, 0.2mM) for B40 s at 4 C and then
cryo-cooling crystals in liquid nitrogen.
X-ray data collection. The X-ray structure of Compound II of APX was solved by
merging the ﬁrst 10 of data from 10 different crystals. The data sets were collected
in-house at 100 K using CuKa radiation (l¼ 1.5418Å) from a Rigaku MicroMax
007HF generator. Crystals of APX were reacted with m-CPBA as above and 20
images of 0.5 oscillation with 1 s exposure per image were recorded on a Rigaku
Saturn 944þ detector to a resolution of 1.8 Å from each crystal. Data were indexed
using iMOSFLM37 then scaled and merged using AIMLESS as part of the CCP4
suite38. The statistics for the X-ray data collection are shown in Supplementary
Table 1. X-ray ﬂuorescence spectra on single crystals of ferric APX and
Compound II were collected using the Vortex detector at Beamline I04, Diamond
Light Source.
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Figure 3 | Comparison of Compound I and Compound II intermediates in
peroxidases and P450s. (a,b) Compounds I (shown in red) in CcP (ref. 18)
and in both P450 and APO (refs 22,23) are Fe(V)¼O species. (c) In P450
and APO, there is a large increase in pKa of the ferryl group going from
Compound I to Compound II (the latter shown in blue), and the ferryl group
is a protonated Fe(IV)–OH (refs 21,24). (d) Compound II of APX is an
Fe(IV)–OH species, as presented in this paper. Bond lengths for CcP-I are
from ref. 17 and for P450-I and P450-II are from refs 21,26.
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Neutron data collection. Preliminary experiments at the BIODIFF beamline39
at the FRM II research reactor in Munich were used to test the experimental
protocols, while full data collection took place using the LADI-III beamline40 at the
Institut Laue-Langevin (ILL), Grenoble. At the wavelengths/energies (Z1Å,
r81meV) typically used for crystallographic experiments, neutrons do not cause
any observable radiation damage effects (discussed in ref. 13). For data collection,
here we used ‘cold’ neutrons with l of 3.2–4.2 Å, corresponding to energies in the
range 8–4.6meV. A large (0.7 0.5 0.4mm3) single crystal of APX was reacted
with m-CPBA as above to form Compound II and was then directly cryo-cooled to
100K in the N2 gas cryo-stream of the LADI-III instrument. Quasi-Laue neutron
diffraction data extending to 2.2 Å resolution were collected at 100K. As is typical
for a Laue experiment, the crystal was held stationary at a different f setting for
each exposure. In total, 15 images were collected (with an average exposure time of
22.3 h per image) from two different crystal orientations. The neutron data were
processed using the program LAUEGEN modiﬁed to account for the cylindrical
geometry of the detector41. The program LSCALE42 was used to determine the
wavelength-normalization curve using the intensities of symmetry-equivalent
reﬂections measured at different wavelengths. No explicit absorption corrections
were applied. These data were then merged in SCALA38. The statistics for the
neutron data collection are shown in Supplementary Table 1 in the supporting
information.
Structure reﬁnement. The crystals used for the data collections were iso-
morphous with the previously published Compound II X-ray structure (PDB ID:
2XIF). All solvent molecules and the ligand were removed from 2XIF, which was
then used as the starting model. The X-ray structure was solved and reﬁned ﬁrst,
then the joint X-ray and neutron reﬁnement was carried out with PHENIX43,44.
H- and D-atoms were added with the program ReadySet44 and D2O molecules
were added based on the neutron Fo–Fc map. The model building was completed
with Crystallographic Object-Oriented Toolkit software45. Determination of the
identity and the position of heme ligand were based on the neutron data only. Joint
X-ray/neutron structural reﬁnement statistics are given in Supplementary Table 1.
Single crystal spectrophotometry. Absorption spectra of single crystals of
Compound II of APX, obtained as outlined above, were collected at 100K using an
Ocean Optics Maya 2,000 PRO spectrometer, with an Ocean Optics DH-2000-BAL
UV-VIS-NIR light source and a Humamatsu S10420 FFT-CCD back thinned
detector with ﬁbre optic coupled to 80mm diameter 4X reﬂective lenses (Optique
Peter, Lentilly, France) and mounted with a custom mount on Rigaku Raxis IV f
drive. The temperature was maintained at 100K with an Oxford Cryosystems
cryostream. Absorption spectra were acquired by means of the Ocean Optics
SpectraSuite software. Single crystal microspectrophotometry was carried out as
previously described18 on single crystals of D2O-exchanged ferric APX that had
been reacted with m-CPBA (0.2mM) or H2O2 (0.2mM) for 40 s at 4 C as above,
followed by cryo-cooling at 100 K.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information. Atomic
coordinates and diffraction data have been deposited in the Protein Data Bank
(accession codes 5JPR and 5JQR).
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